Premium
Pentoxifylline and Thalidomide Fail to Reduce Hepatic Steatosis During Total Parenteral Nutrition and Bowel Rest in the Rat
Author(s) -
Vromen Amos,
Spira Ram M.,
Bercovier Herve,
Berry Elliot,
Freund Herbert R.
Publication year - 1997
Publication title -
journal of parenteral and enteral nutrition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.935
H-Index - 98
eISSN - 1941-2444
pISSN - 0148-6071
DOI - 10.1177/0148607197021004233
Subject(s) - pentoxifylline , parenteral nutrition , medicine , steatosis , gastroenterology , thalidomide , sepsis , enteral administration , multiple myeloma
Background: We suggested that the continuous translocation of endotoxin from Gram‐negative bacterial overgrowth during bowel rest and total parenteral nutrition (TPN) causes the release of tumor necrosis factor (TNF), resulting in liver damage and hepatic dysfunction. Because TPN‐induced hepatic steatosis was significantly reduced by the monoclonal antibodies against TNF, we attempted a more clinically applicable approach using pentoxifylline and thalidomide. Methods: A control group (group I) fed rat chow and four groups of rats receiving TPN were studied. Group II received TPN only; group III, TPN and 100 mg/kg/d pentoxifylline; group IV, TPN and 200 mg/kg/d pentoxifylline; and group V, TPN and 5 mg/kg/d thalidomide. On day 7, total liver fat was determined. Results: Bowel rest and TPN resulted in a significant (p <.0005) increase in liver fat content that was unaltered by either pentoxifylline or thalidomide. Conclusions: Our results show no role for pentoxifylline or thalidomide in reducing TPN‐associated hepatic steatosis. (journal of Parenteral and Enteral Nutrition 21: 233–234 , 1997)